Items per page
Sort by

Send to:

Choose Destination

Results: 15


Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors.

Rogers MS, Novak K, Zurakowski D, Cryan LM, Blois A, Lifshits E, Bø TH, Oyan AM, Bender ER, Lampa M, Kang SY, Naxerova K, Kalland KH, Straume O, Akslen LA, Watnick RS, Folkman J, Naumov GN.

Mol Cancer Res. 2014 May;12(5):754-64. doi: 10.1158/1541-7786.MCR-13-0532-T. Epub 2014 Feb 26.


Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia.

Øyan AM, Anensen N, Bø TH, Stordrange L, Jonassen I, Bruserud Ø, Kalland KH, Gjertsen BT.

BMC Cancer. 2009 Mar 5;9:77. doi: 10.1186/1471-2407-9-77.


Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.

Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4834-9. doi: 10.1073/pnas.0806514106. Epub 2009 Mar 4.


Genomic diversity among Beijing and non-Beijing Mycobacterium tuberculosis isolates from Myanmar.

Stavrum R, Valvatne H, Bø TH, Jonassen I, Hinds J, Butcher PD, Grewal HM.

PLoS One. 2008 Apr 9;3(4):e1973. doi: 10.1371/journal.pone.0001973.


Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in acute myeloid leukemia.

Oyan AM, Bø TH, Jonassen I, Ulvestad E, Tore Gjertsen B, Bruserud O, Kalland KH.

Curr Pharm Biotechnol. 2007 Dec;8(6):344-54. Review.


Characterization of early stages of human B cell development by gene expression profiling.

Hystad ME, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L, Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, Staudt LM, Smeland EB.

J Immunol. 2007 Sep 15;179(6):3662-71. Erratum in: J Immunol. 2009 May1;182(9):5882.


Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization.

Petersen K, Oyan AM, Rostad K, Olsen S, Bø TH, Salvesen HB, Gjertsen BT, Bruserud O, Halvorsen OJ, Akslen LA, Steen VM, Jonassen I, Kalland KH.

Anal Biochem. 2007 Jul 1;366(1):46-58. Epub 2007 Mar 18.


Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer.

Halvorsen OJ, Rostad K, Øyan AM, Puntervoll H, Bø TH, Stordrange L, Olsen S, Haukaas SA, Hood L, Jonassen I, Kalland KH, Akslen LA.

Clin Cancer Res. 2007 Feb 1;13(3):892-7.


ERG upregulation and related ETS transcription factors in prostate cancer.

Rostad K, Mannelqvist M, Halvorsen OJ, Oyan AM, Bø TH, Stordrange L, Olsen S, Haukaas SA, Lin B, Hood L, Jonassen I, Akslen LA, Kalland KH.

Int J Oncol. 2007 Jan;30(1):19-32.


CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles.

Oyan AM, Bø TH, Jonassen I, Ulvestad E, Gjertsen BT, Kalland KH, Bruserud O.

Cytometry B Clin Cytom. 2005 Mar;64(1):18-27.


Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.

Halvorsen OJ, Oyan AM, Bø TH, Olsen S, Rostad K, Haukaas SA, Bakke AM, Marzolf B, Dimitrov K, Stordrange L, Lin B, Jonassen I, Hood L, Akslen LA, Kalland KH.

Int J Oncol. 2005 Feb;26(2):329-36.


LSimpute: accurate estimation of missing values in microarray data with least squares methods.

Bø TH, Dysvik B, Jonassen I.

Nucleic Acids Res. 2004 Feb 20;32(3):e34.


A fast top-down method for constructing reliable radiation hybrid frameworks.

Bø TH, Jonassen I, Eidhammer I, Helgesen C.

Bioinformatics. 2002 Jan;18(1):11-8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk